

## INVOKANA

### GPI CODING:

INVOKANA 277000200003\*\*

### DESCRIPTION:

Canagliflozin is the first FDA approved drug in its class to be used as monotherapy in adjunct with diet and exercise for the treatment of type 2 diabetes mellitus. In clinical trials, canagliflozin proved to significantly improve glycemic control in patients with type 2 diabetes mellitus inadequately controlled on diet and exercise.

### APPROVAL DURATION:

Approval duration: indefinite

### CRITERIA FOR INVOKANA

- I. The member does not have any of the following contraindications or exclusions to therapy:
  - a. Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 45 mL/min/1.73 m<sup>2</sup>)
  - b. End stage renal disease (ESRD)
  - c. Currently requiring dialysis
  - d. Diabetic ketoacidosis
  - e. Pediatric patient (under the age of 18 years)
- AND**
- II. The member has a diagnosis of type 2 diabetes mellitus and has had an inadequate response to diet and exercise alone **AND**
- III. The member has tried and had an inadequate response or intolerance to metformin and one additional anti-diabetic agent from a different class (ie. sulfonylureas, TZDs, GLP-1 agonist, DPP4 inhibitor)